Commercialisation director joins Edinburgh BioQuarter

Life sciences entrepreneur Michael Capaldi joins Scotland\'s flagship project

Michael Capaldi, scientist and life sciences entrepreneur, has been named as director of commercialisation for the Edinburgh BioQuarter – Scotland’s flagship project for the life sciences sector.

Capaldi will lead a team of up to 15 people to progress a £12m commercialisation project that will bridge the gap between industry and research.

Capaldi has more than 26 years’ experience in the pharmaceutical and life sciences industries within the UK, Europe and the US.

You may also like

Research & Development

University of Edinburgh to collaborate with Galapagos on cancer therapies

Two-year partnership with plans to extend
Research & Development

Cirena and Epigenica launch technologies to accelerate genome editing and epigenomic research

Two life sciences companies have announced new technologies designed to address long-standing bottlenecks in genome editing and epigenomic analysis, offering faster timelines and improved reproducibility for researchers in academia and industry
Research & Development

PSI launches platform to speed up site ID, startup and enrolment in pivotal studies

SYNETIC is designed to speed up site identification, startup and patient enrollment in pivotal clinical trials
Ingredients

Piramal Pharma Solutions introduces tablet-in-capsule capabilities

Enhancing dosing flexibility and patient-centric drug delivery
Research & Development

AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic

The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies
Research & Development

Baseline Therapuetics launches to advance GLP-1 Phase III Programme in Alcohol Use Disorder

The clinical-stage biotech has launched to progress BT-001, a once-weekly GLP-1 receptor agonist, into FDA-aligned Phase III trials for alcohol use disorder, with studies planned to begin in 2026
Research & Development

Researchers identify early signs of Parkinson's in the blood

Researchers at Chalmers University of Technology have identified early-stage Parkinson’s disease biomarkers detectable in blood, revealing a limited diagnostic window that could enable screening and earlier intervention years before motor symptoms appear
Subscribe now